President Donald Trump's son-in-law Jared Kushner has presented a $50 billion investment plan for economic growth and peace in the Middle East that has been greeted with...World Politicsread more
Stocks should rally if the U.S. and China agree to new negotiations and a ceasefire in the trade war, but the economic impact of tariffs will continue.Market Insiderread more
The trade war between Beijing and Washington appears to have depressed Chinese property purchases in the United States. China's own actions may also be playing a role.Real Estateread more
Tesla CEO Elon Musk sent out another email to his employees, pushing them to aim for a record number of vehicle deliveries to end the second quarter of 2019.Technologyread more
More than 300 companies are talking to government officials in Washington about how detrimental the trade war is.Marketsread more
Democrats want Mueller's testimony on his probe into Russian interference in the 2016 election and Trump's efforts to influence it.Politicsread more
The Senate is expected to pass its own version of the border aid legislation, while the Trump administration has threatened to veto both bills.Politicsread more
Some 4 million people have fled the South American country since 2015 amid an economic meltdown.World Politicsread more
Japanese designer Undercover posted on its Instagram account a photo of protesters with the slogan "no extradition to China," the Financial Times reported.China Politicsread more
Powell stresses the central bank's independence in a speech that comes amid continuous pressure from the White House to cut interest rates.The Fedread more
Stocks in Asia were subdued on Wednesday after U.S. Federal Reserve Chairman Jerome Powell tempered expectations for a potential interest rate cut.Asia Marketsread more
The Food and Drug Administration will hold its first public hearings on CBD in April as the agency weighs rules allowing companies to add the popular cannabis-based compound to food, Commissioner Scott Gottlieb said Wednesday.
"We're deeply focused on this. We have taken on other hard challenges before," Gottlieb told the House Appropriations Committee on Wednesday. "You have my commitment I'm focused on this one."
Gottlieb said he has heard Congress "loud and clear" when it legalized hemp products, including CBD, in December and is putting together a working group of senior officials to work on the new rules. The FDA will kick off its rulemaking process with a public hearing in April, he said. However, Gottlieb warned the committee that it will not be a "straightforward" process.
CBD, short for cannabidiol, is a non-psychoactive compound found in the cannabis plant that promises to relax the body without altering the mind. While the federal government legalized CBD that's derived from hemp, a close cousin of marijuana, the FDA's rules still prohibit companies and restaurants from adding it to food or drinks.
Gottlieb floated what a possible framework might look like. He suggested high concentrations might be regulated as a drug that has more stringent oversight while lower concentrations could be categorized as food products that come with an easier review process.
He said the cannabis compound has possible therapeutic benefits and a regulatory process for pharmaceutical-grade CBD will give drugmakers more incentive to research and develop CBD-derived drugs.
"There is not a good proxy for us doing this through regulation, and if we get comments back and find this is sufficiently complicated for the agency, we will come back and have a conversation with Congress on with how we might be able to work together on this," Gottlieb said. He added that Congress may need to intervene with additional legislation if the FDA thinks it will take two or more years to implement the rules.
Congress' legalization of CBD derived from hemp was supposed to pave the way for a booming new industry. Although companies are technically prohibited from adding CBD to food, drinks and dietary supplements, many are doing it anyway.
There's plenty of interest among consumer product companies, but the lack of clear regulation from the FDA has kept some big companies on the sidelines for now. And the CBD industry is begging for regulation.